Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Citi
US Department of Justice
Colorcon
Healthtrust
Boehringer Ingelheim
Moodys
Express Scripts
Novartis

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,368,469

« Back to Dashboard

Which drugs does patent 7,368,469 protect, and when does it expire?

Patent 7,368,469 protects ALTACE and is included in two NDAs.

This patent has forty-four patent family members in thirty-one countries.
Summary for Patent: 7,368,469
Title:Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
Abstract:Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
Inventor(s): Scholkens; Bernward (Kelkheim, DE), Bender; Norbert (Hofheim, DE), Rangoonwala; Badrudin (Hofheim, DE), Dagenais; Gilles (St.-Nicholas, CA), Gerstein; Hertzel (Hamilton, CA), Yusuf; Salim (Carlisle, CA)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt, DE)
Application Number:11/490,061
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,368,469

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 AB RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 AB RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 AB RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 AB RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pfizer ALTACE ramipril TABLET;ORAL 022021-001 Feb 27, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,368,469

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1216038 ➤ Subscribe
Russian Federation 2005141759 ➤ Subscribe
Russian Federation 2276997 ➤ Subscribe
Serbia 50377 ➤ Subscribe
Yugoslavia 8502 ➤ Subscribe
Poland 353199 ➤ Subscribe
New Zealand 530702 ➤ Subscribe
New Zealand 517468 ➤ Subscribe
Norway 331616 ➤ Subscribe
Norway 20020978 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
Boehringer Ingelheim
Cantor Fitzgerald
Harvard Business School
Accenture
Chubb
Novartis
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot